tbuckley/cabot-search huggingface dataset:
The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study.
Authors: I. Griebsch, I. Lang, U. Sartorius, E. Van Cutsem
Journal: Journal of Clinical Oncology (2011)

3626 Background: In the CRYSTAL study cetuximab (cet) added to 1st-line chemotherapy (CT) significantly improved tumor response compared with CT alone in patients (pts) with KRAS wild-type (wt) mCRC, confirming existing data in this setting. Response to CT has been reported to lead to a corresponding increase in QoL, and QoL scores to predict overall survival in mCRC. In this exploratory analysis tumor response and QoL was investigated in pts from the CRYSTAL study. Methods: Pts were classified as responders (Rs) or non-responders (NRs) according to best overall response. QoL was assessed using single-item symptoms questions from the EORTC QLQ-C30 (q8-10, q12-18). Pts at baseline were considered symptomatic if they answered “quite a bit” or “very much” and asymptomatic if they answered “not at all” or “a little” to any one of the symptoms questions. Analysis was performed in all treatment groups (gps) on the change in symptoms in pts considered symptomatic or asymptomatic at baseline. Results: 471 of 627 KRAS wt pts assessed for QoL had baseline data showing they were symptomatic or asymptomatic. In pts asymptomatic at baseline (n=278) there were more Rs (58%) than NRs (42%). In pts symptomatic at baseline (n=193), there were less Rs (40%) than NRs (60%). At week 8 in all treatment gps, in pts symptomatic at baseline more Rs than NRs became asymptomatic (Table). In pts asymptomatic at baseline, in the CT + cet gp at week 8, 61% of Rs remained asymptomatic compared with 50% of NRs. Data from week 16 and 24 also showed trends in favor of Rs in symptomatic or asymptomatic pts at baseline and will be presented. Conclusions: Rs who are symptomatic at baseline experience higher symptom relief than NRs. Furthermore, Rs who are asymptomatic at baseline are more likely to remain asymptomatic post baseline than NRs. These findings are independent of treatment. Pts symptomatic at baseline who became asymptomatic by treatment and response status, n (%). Overall treatment CT CT + cet R (n=78) NR (n=115) R (n=32) NR (n=72) R (n=46) NR (n=43) Status at week 8 Asymptomatic 29 (37) 13 (11) 8 (25) 10 (14) 21 (46) 3 (7) Symptomatic 39 (50) 58 (50) 19 (59) 32 (44) 20 (43) 26 (60) Missing 10 (13) 44 (38) 5 (16) 30 (42) 5 (11) 14 (33)
Focus in glaucoma may change from keeping fluid out to letting fluid out
Authors: P. Cotton
Journal: JAMA (1993)

CONVENTIONAL wisdom and treatment may have to give way as new evidence suggests that glaucoma treatments may be aimed the wrong way. Future therapy will likely be designed to clean out the trabecular meshwork encircling the cornea to allow fluid out, rather than to reduce the flow into the eye as most current treatments do. So suggest findings presented at a Research to Prevent Blindness science writers seminar in Universal City, Calif. If theory is confirmed in an ongoing phase III multicenter trial, one new treatment aimed at the trabecular meshwork may be needed as infrequently as once a year, predicts one researcher. "We know unequivocally that for all forms of glaucoma, it is not a disease of excess formation of fluid, it is a disease of impaired drainage," says David L. Epstein, MD, professor and chair of ophthalmology, Duke University Medical Center, Durham, NC. Ted S. Acott, PhD, another
Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin’s Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d’Études des Lymphomes de l’Adulte H89 Trial
Authors: Christophe Fermé, Nicolas Mounier, Marine Diviné, Pauline Brice, Aspasia Stamatoullas, Oumedaly Reman, Laurent Voillat, Jérôme Jaubert, Pierre Lederlin, Philippe Colin, Françoise Berger, Gilles Salles
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To evaluate prospectively the feasibility and efficacy of early intensive therapy, including intensified cytoreductive chemotherapy (CT) and high-dose CT (HDCT) followed by autologous stem-cell transplantation (ASCT), in patients with advanced Hodgkin’s disease (HD) who failed to respond completely or relapsed after initial treatment. PATIENTS AND METHODS: Among 533 eligible patients with newly diagnosed stage IIIB-IV HD enrolled in the H89 trial, all 157 patients with induction failure (IF) (n = 67), partial response (PR) of less than 75% (n = 22), or relapse (n = 68) were included in this study. Planned salvage therapy included mitoguazone, ifosfamide, vinorelbine, and etoposide monthly for two to three cycles followed by high-dose carmustine, etoposide, cytarabine, and melphalan with ASCT. RESULTS: With a median follow-up of 50 months, the 5-year survival estimates were 30%, 72%, and 76% for the IF, PR, and relapse groups, respectively (P = .0001), 71% for the 101 patients given HDCT, and 32% for the 48 patients treated without HDCT (P = .0001). Multivariate analysis using time-dependent Cox model indicated that B symptoms at progression, salvage without HDCT, and chemoresistant disease before HDCT were significantly associated with shorter overall survival. CONCLUSION: Early intensive therapy improves the outcomes of patients with advanced HD who failed to respond completely to initial treatment and those who relapsed with adverse prognostic factors. However, for patients with IF and chemoresistant disease, this approach remains unsatisfactory.
Dust And Its Dangers
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transient atrioventricular standstill. Etiology and management
Authors: K. Gupta
Journal: JAMA (1975)

Four patients with different clinical conditions had transient cardiac standstill for periods of up to 22.5 seconds. All patients showed signs of cerebral ischemia and required cardiac resuscitation. In one patient, the standstill was thought to be the result of a transient increase in the vagal tone, and no long-term therapy was required. In the second patient, cardiac standstill occurred during hospitalization for impending myocardial infarction. Coronary arteriography followed by coronary artery surgery was performed, and there were no further episodes of standstill. In the third patient, standstill was probably related to long-term ingestion of propranolol hydrochloride, and was not observed after this medication was discontinued. In the fourth patient, standstill was the result of the sick sinus syndrome, and a permanent pacemaker was inserted. Standstill of both atria and ventricles may occur under different clinical settings, and management of arrhythmia should be guided by the etiology of the arrhythmia. (<i>JAMA</i>234:1038-1042, 1975)
Venereal transmission of hepatitis B virus
Authors: R. O. Valdiserri
Journal: JAMA (1979)

<h3>To the Editor.—</h3> The observations of Kiernan and Powers (241:585, 1979), that patients who are carriers for hepatitis B surface antigen often have inappropriate responses to questions about transmission risks, represent an important clinical point of information. Regardless of the small size of their study, the inference can be made that patients are often not clearly informed as to the infectious nature of their illness. This in part may be due to the rapidly growing mass of information surrounding hepatitis B and the changing clinical concepts associated with that growth. Although the venereal nature of this infection has long been recognized,<sup>1</sup>there have been few attempts to study its sexual transmission in a systematic fashion. The high rate of infection in homosexual men (238: 2625, 1977) is probably partially related to the dearth of public health measures aimed at patient education and prevention of spread. To this end, the
Ebola Hinders Polio Surveillance
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AZACITIDINE (VIDAZA®) IN PEDIATRIC PATIENTS WITH RELAPSED ADVANCED MDS: RESULTS OF A PHASE I/II STUDY BY THE ITCC CONSORTIUM AND THE EWOG-MDS GROUP: STUDY ITCC-015
Authors: N. K. van Eijkelenburg, M. M. van den Heuvel-Eibrink, H. Hasle, C. M. Niemeyer, M. N. Dworzak, M. Zecca, M. I. Lopez, R. Hoogendijk, J. Janssen, A. Huitema, C. M. Zwaan
Journal: HemaSphere (2019)
Tourism-acquired Mansonella ozzardi microfilaremia in a regular blood donor
Authors: P. F. Weller
Journal: JAMA (1978)

<i>MANSONELLA ozzardi</i>is a human filarial parasite whose distribution is limited to areas of South and Central America and to the West Indies. In the case of other filarial parasites, brief residence in or travel to endemic areas usually does not eventuate in detectable microfilaremia. For example, of more than 10,000 American military personnel with symptomatic evidence of filarial infection with<i>Wuchereria bancrofti</i>while stationed in the Pacific during World War II, fewer than 20 had detectable microfilaremia, and this was usually transient and of low levels.<sup>1</sup>In the case reported here, an asymptomatic man with only brief exposures in endemic areas during Caribbean vacations was found to have persistent<i>M ozzardi</i>microfilaremia. The patient was a regular blood donor, and microfilaremia was initially detected on a blood smear examined at the time of blood donation. <h3>Report of a Case</h3> A healthy 46-year-old man periodically donated blood at a
Red Blood Cell Diameters.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POSTVACCINAL MYELITIS
Authors: R. A. Perritt
Journal: JAMA (1930)

While cases of encephalitis following antismallpox vaccination are not rare, those of postvaccinal myelitis are unusual. The case here recorded is of great interest also because of the long duration. At the time the patient entered the hospital, three and one-half years had elapsed since the onset. <h3>REPORT OF CASE</h3><h3>History.</h3> —A white girl, aged 18, entered the neurologic service of the Cook County Hospital because of inability to walk. Three and one-half years previously she had been vaccinated on the left arm against smallpox. The next day the arm became tender, red and swollen. Two days later she developed a high fever, severe headaches, and pain in the legs and back. Her legs were drawn up, her head was retracted and she had to be catheterized. Nine days after the vaccination the acute symptoms subsided, but the patient's left arm and both legs became completely paralyzed; sensation was not
Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: Evidence of treatment as prevention from the SToP-C study
Authors: Gregory Dore, Behzad Hajarizadeh, Jason Grebely, Marianne Byrne, Pip Marks, Janaki Amin, Hamish Mcmanus, Tony Butler, Peter Vickerman, Natasha Martin, John Mchutchison, Diana Brainard, Carla Treloar, Andrew Lloyd
Journal: Journal of Hepatology (2020)
Physical activity platform to improve bone health in cancer survivors.
Authors: Cathy Skinner
Journal: Journal of Clinical Oncology (2019)

TPS11632 Background: Cancer treatment-induced bone loss and the subsequent risk of fractures in both men and women is a significant burden on national health care. US cancer survivors will reach 18 million by 2022 and by 2025 and the projected burden of osteoporosis is $25.3B. Cancer patients treated with medications that lower hormone levels face an increased risk of fractures. Clinical studies report that moderate-intensity resistance exercises prevent a decline in bone health in female cancer survivors, and that strength training may reduce complications such as fatigue, muscle wasting, and bone loss. Unfortunately, only a small percentage of female cancer survivors engage in and adhere to a strength training exercise routine. Several factors account for this low level of engagement such as poor awareness of the benefits of exercise, lack of motivation, and the lack of affordable and easily accessible exercise programs designed for cancer survivors. Internet-based self-managed programs of exercises and guidance can potentially address these problems, and can be scaled for broader dissemination. Methods: The Thrivors platform seeks to shift the current paradigm of poor adherence to exercise by providing an affordable and accessible means of improving outcomes for cancer survivors. Thrivors plus Bone Health (Thrivors+BH), will be a first-of-its-kind offering of clinically validated bone health exercises that can be customized to a cancer survivor's pain and energy levels, with several novel interactive feedback features. The product has supportive modules for connecting with a community of other users, mindfulness training, nutritional advice and educational information. The Thrivors platform is scalable, device-agnostic, and allows analysis of de-identified usage data. The two versions of the platform will be deployed in a 20-week, two-arm randomized controlled trial of 50 breast cancer survivors. Adherence to exercise sessions (primary outcome) and platform usage will be measured by platform software, while user engagement (secondary outcomes) will be assessed by surveys. Differences between primary and secondary outcomes for the control and intervention groups will be evaluated. Usage statistics, motivational responses and user feedback will be used to further refine platform features and content. Clinical trial information: NCT03651037.
In This Issue
Journal: Journal of Clinical Investigation (2006)

PTEN blocks the way for TregsNaturally occurring CD4 + CD25 + Tregs function to prevent self-reactive T cells from destroying self-tissues.But harnessing the therapeutic potential of Tregs is hampered because, unlike nonregulatory T cells, they do not proliferate in vitro when stimulated through their TCR, and, unlike activated CD4 + CD25 + effector T cells, they do not undergo cell division in response to IL-2.Walsh and colleagues had previously observed that signaling downstream of the receptor for IL-2 was distinct in Tregs and nonregulatory T cells.In particular, increased expression of phosphatase and tensin homolog (PTEN), which is a negative regulator of PI3K signaling pathways, was detected in Tregs.In this issue, the authors now report that in mice, T cell-specific deletion of Pten results in the development of normal numbers of Tregs but that PTEN-deficient Tregs proliferate when stimulated with IL-2 ex vivo and undergo increased homeostatic proliferation in vivo (pages 2521-2531).Importantly, PTEN-deficient Tregs retained their suppressive function in vitro and in vivo, indicating that loss of PTEN only affects the IL-2-hypoproliferative phenotype of these cells.This study identifies one of the molecular regulators of the IL-2-hypoproliferative phenotype of Tregs and could provide researchers with a way to overcome one of the biggest obstacles to harnessing their therapeutic potential.
Coronary arteriography
Authors: H. Kasparian
Journal: JAMA (1966)

Coronary arteriography is a radiographic exploration of the coronary vessels in living subjects. This procedure was initiated about 32 years ago when Peter Rousthöi demonstrated angiographically the coronary arteries in intact experimental animals.<sup>1</sup>Radner, in 1945, was able to perform the technique in the living man.<sup>2</sup>Although the initial attempts at vascular opacification were viewed with considerable ridicule by skeptical onlookers, enough experience has been accumulated to consider the procedure safe and reasonably accurate. This accomplishment was made possible through the development of new contrast media and significant improvement of roentgenographic and catheterization techniques. Presently, two basically different approaches are used for contrast visualization of the coronary arteries: catheter thoracic aortography and selective catheter coronary arteriography.<sup>3</sup>In thoracic aortography, improved filling of the coronary arteries is accomplished when attempts are made to decrease the cardiac output, prolong the ventricular diastole, or obstruct the thoracic aorta. Catheterization of
Respiratory Medicine
Journal: Thorax (1990)

Occupational asthma in a pharmaceutical worker exposed to hydralazine exposure o lactose (15 min) hydralazine (30 min) BDT pre .dA. . .pre 0 20 40 6 2 4 6 8 minutes hours timeChanges in FEV, on the control day of exposure to lactose and on the last day of exposure to hydralazine.BDT-inhaled salbutamol (200 ,g).No evidence for an immunological mechan- ism of the IgE or IgG type could be found.This is true of several pharmaceutical products that cause occupational asthma."2Although no case of occupational asthma due to hydralazine has been reported to our knowledge, Fueki-without giving any objective evidence-mentioned that it could cause rhinitis.'We wish to thank Katherine Tallman for reviewing the manu- script.
HMG-CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells
Authors: Joan Llevadot, Satoshi Murasawa, Yasuko Kureishi, Shigeki Uchida, Haruchika Masuda, Atsuhiko Kawamoto, Kenneth Walsh, Jeffrey M. Isner, Takayuki Asahara
Journal: Journal of Clinical Investigation (2001)

Endothelial progenitor cells (EPCs) have been isolated from circulating mononuclear cells in peripheral blood and shown to incorporate into foci of neovascularization, consistent with postnatal vasculogenesis. These circulating EPCs are derived from bone marrow and are mobilized endogenously in response to tissue ischemia or exogenously by cytokine stimulation. We show here, using a chemotaxis assay of bone marrow mononuclear cells in vitro and EPC culture assay of peripheral blood from simvastatin-treated animals in vivo, that the HMG-CoA reductase inhibitor, simvastatin, augments the circulating population of EPCs. Direct evidence that this increased pool of circulating EPCs originates from bone marrow and may enhance neovascularization was demonstrated in simvastatin-treated mice transplanted with bone marrow from transgenic donors expressing β-galactosidase transcriptionally regulated by the endothelial cell-specific Tie-2 promoter. The role of Akt signaling in mediating effects of statin on EPCs is suggested by the observation that simvastatin rapidly activates Akt protein kinase in EPCs, enhancing proliferative and migratory activities and cell survival. Furthermore, dominant negative Akt overexpression leads to functional blocking of EPC bioactivity. These findings establish that augmented mobilization of bone marrow–derived EPCs through stimulation of the Akt signaling pathway constitutes a novel function for HMG-CoA reductase inhibitors.
INDIA
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response to: ‘Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’’ by Cui<i>et al</i>
Authors: Ke-Qi Liu, Jiangwei Xia, Qiu-Ping Chen, Jian-Qiang Yang, Hou-Feng Zheng
Journal: Annals of the Rheumatic Diseases (2020)

Response to: 'Correspondence on 'Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation